Abstract #2481

Tumor necrosis factor (TNF) antagonist therapy in small bowel Crohn’s disease (CD): association of the apparent diffusion coefficient (ADC) with treatment response.

Bradley Spieler¹, Hector De Jesus¹, Christopher Rouse¹, Catherine Hudson², Scott Kleinpeter³, Catherine Batte⁴, Raman Danrad¹, and Kara De Felice⁵

¹Radiology, LSUHSC New Orleans, New Orleans, LA, United States, ²Internal Medicine, LSUHSC New Orleans, New Orleans, LA, United States, ³School of Medicine, LSUHSC New Orleans, New Orleans, LA, United States, ⁴LSU, Baton Rouge, LA, United States, ⁵Gastroenterology, LSUHSC New Orleans, New Orleans, LA, United States

Diffusion weighted imaging (DWI) has proven beneficial in the assessment of disease activity and therapeutic response in a myriad of pathology. Studies have shown an inversely proportional correlation between bowel inflammation in Crohn’s disease (CD) and apparent diffusion coefficient (ADC) values of involved bowel wall. This beckons an intriguing opportunity for gauging treatment response, particularly with respect to some of the most commonly used agents, tumor necrosis factor (TNF) antagonists. This study retrospectively measured the ADC value of affected small bowel segments before and after anti-TNF infusion therapy and compares it to the clinical response in patients with active CD.

This abstract and the presentation materials are available to members only; a login is required.

Join Here